Galectin Therapeutics to Present at the American Association for the Study of Liver Disease (AASLD) Liver Meeting 2025

Core Insights - Galectin Therapeutics Inc. is participating in the AASLD Liver Meeting 2025, presenting data from the NAVIGATE trial on belapectin for MASH cirrhosis treatment [1][2] - The NAVIGATE trial data has been recognized for its significance in addressing the urgent need for therapies in MASH cirrhosis, highlighting belapectin's potential impact on treatment [2] Presentation Details - The oral presentation titled "Belapectin Reduces Liver Stiffness Progression and Prevents Varices at 18 Months in MASH Cirrhosis: Results from the NAVIGATE Trial" will take place on November 10, 2025 [3] - A poster presentation titled "Belapectin Maintains a Favorable Trend in Reducing Variceal Development Over 36 Months in MASH Cirrhosis: Results from the NAVIGATE Trial" is scheduled for November 8, 2025 [3] Company Overview - Galectin Therapeutics focuses on developing therapies for chronic liver disease and cancer, with belapectin as its lead drug targeting galectin-3 [4] - The company has received Fast Track designation from the FDA for belapectin, which is aimed at treating MASH with cirrhosis, a significant medical need [4] - Additional development programs include cancer immunotherapy, with the success of these programs dependent on finding suitable partnerships [4]